Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs

A technology for antipsychotics and weight gain, applied in the direction of drug combinations, pharmaceutical formulations, neurological diseases, etc., can solve the problems of exacerbation of psychosis, exacerbation of symptoms, no consistent display of beneficial effects, etc.

Inactive Publication Date: 2010-11-17
黛安娜·麦金托什 +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[5] In addition to the health risks posed by weight gain and metabolic syndrome, patients may choose to discontinue treatment, often leading to worsening of their psychosis
Metformin does not consistently show beneficial effect in reversing weight gain associated with psychiatric drugs
Unfortunately, as noted above, weight gain often causes patients to discontinue treatment prematurely, leading to worsening symptoms
Although the biological mechanisms responsible for weight gain and the associated metabolic syndrome in patients receiving psychiatric drugs have not been fully elucidated, new methods and compositions for preventing or reducing this serious side effect of conventional therapy are urgently needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] A 31-year-old female was diagnosed with bipolar disorder at the age of 17. She suffers from panic attacks, obsessive-compulsive disorder, and social anxiety disorder. Three years ago, while on carbamazepine and olanzapine (20 mg per day), she gained 60 pounds, bringing her weight to 210 pounds. Two years ago, while receiving lamotrigine alone (400 mg per day), she weighed 150 lbs.

[0050] When the patient was given pramipexole (0.25 mg twice daily) in combination with olanzapine (20 mg daily), she lost 11 pounds (from 187 pounds to 176 pounds).

Embodiment 2

[0052] A 34-year-old female patient with post-traumatic stress disorder and major depression. She had been given quetiapine (300 mg per day), which caused her to gain 20 pounds (to 155 pounds). Therefore, quetiapine was discontinued. Tried risperidone (2 mg daily), but she gained another 12 pounds (to 167 pounds) and developed galactorrhea. Therefore, risperidone was discontinued.

[0053] On the day when risperidone was stopped, olanzapine (5 mg per day) and pramipexole (0.125 mg per day) were co-administered. The galactorrhea stopped by the second week and the weight was reduced to 160 lbs. The final dose of pramipexole is 0.25 mg twice daily.

Embodiment 3

[0055] A 34-year-old female diagnosed with bipolar II disorder suffered from panic attacks and post-traumatic stress disorder. She did not respond to a boost with risperidone and quetiapine, so she was started on olanzapine at a dose of 5 mg per day, which resulted in a weight gain from 188 to 202 pounds.

[0056] The olanzapine dose was increased to 10 mg per day in combination with pramipexole at a daily dose of up to 0.75 mg per day. This resulted in a marked decrease in appetite and weight was maintained at 202 lbs, but prednisone 5 mg per day was added for joint pain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods and compositions for preventing or reducing weight gain and associated metabolic syndrome in patients receiving atypical antipsychotic drugs for treatment of mental illnesses are described. The invention comprises administering to a patient in need of treatment an effective amount of a dopamine agonist in conjunction with an effective amount of an atypical antipsychotic drug. In one embodiment of the invention, the dopamine agonist is pramipexole. The dopamine agonist may be administered in a low dose, such as less than 1 mg per day of pramipexole. Examples of atypical antipsychotic drugs which may be administered in conjunction with the dopamine agonist include clozapine, olanzapine, quetiapine and risperadone.

Description

[0001] related application [0002] This application claims the benefit of the filing date of US Provisional Patent Application 60 / 985,563, filed November 5, 2007, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to methods and compositions for preventing or reducing weight gain and associated metabolic syndrome in patients receiving atypical antipsychotics for the treatment of psychosis. Background technique [0004] In addition to the inherent morbidity and functional decline of disease symptoms, there are many physical health risks associated with severe mental illness and their treatment. Chief among those physical health risks is the increased incidence of obesity and the associated metabolic syndrome. [1] [0005] Metabolic syndrome was defined by the World Health Organization (WHO) in 1998 as type 2 diabetes mellitus or the presence of impaired glucose tolerance or insulin resistance associated with tw...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/473A61K31/4045A61K31/428A61K31/519A61K31/551A61K31/554A61P3/04A61P3/10
CPCA61K45/06A61K31/551A61K31/5513A61K31/519A61K31/554A61K31/4045A61K31/428A61K31/473A61P25/18A61P25/22A61P3/04A61P3/06A61P43/00A61P3/10A61K2300/00
Inventor 黛安娜·麦金托什凯文·谢尔尼斯帝德
Owner 黛安娜·麦金托什